FDA PreCheck Pilot Program Structure

Why It Matters

By front‑loading facility evaluation, PreCheck shortens time‑to‑market for domestic drug production, strengthening supply chain resilience and lowering development costs for manufacturers.

Key Takeaways

• Program offers early FDA engagement via Pre‑Operational Reviews.
• Type V DMF serves as a single, reusable facility repository.
• Phase 1 readies facilities; Phase 2 speeds application review and inspection.
• Participants gain faster inspection timelines and potential cost savings.

Pulse Analysis

The FDA’s PreCheck Pilot Program arrives at a moment when U.S. policymakers and industry leaders are scrambling to fortify the domestic drug supply chain. Traditional facility approvals often stretch over years, creating bottlenecks that delay critical medicines. By institutionalizing early, structured dialogue between manufacturers and regulators, PreCheck aims to embed good manufacturing practices at the design stage, reducing the risk of costly retrofits and compliance setbacks later in the product lifecycle.

Phase 1 centers on the Pre‑Operational Review (POR) and the creation of a Type V Drug Master File (DMF). The POR provides a step‑by‑step framework—design review, pre‑construction review, equipment qualification, and pre‑production assessment—delivered through teleconferences, emails, or site visits. Simultaneously, the Type V DMF aggregates all facility data into a single, confidential repository that can be referenced across multiple drug applications. This “qualify once, reference many” approach not only streamlines FDA’s review workload but also gives manufacturers a reusable compliance asset, cutting repetitive documentation efforts.

In Phase 2, the groundwork laid in Phase 1 translates into accelerated application reviews and earlier inspection decisions. Pre‑submission meetings allow the agency to flag facility‑related CMC issues before a New Drug Application (NDA) or Biologics License Application (BLA) is filed, effectively front‑loading the review clock. For companies, this can shave months off the approval timeline and lower overall development costs, while the FDA benefits from a more predictable, data‑rich assessment process. As the pilot matures, its flexible structure could become a permanent pathway, reshaping how new drug manufacturing sites are brought online across the United States.